Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ast-487. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET known ✓ | P07949 | 3/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 7/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 1.00 |
| ▸ | ABL1 | P00519 | 4/20 | 1.00 |
| ▸ | SRC | P12931 | 4/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | BCR | P11274 | 3/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | FER | P16591 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CDK8 | P49336 | 2/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ast-487 SCHEMBL29435006 | 1.00 | HCK (1.00) | HCKMKNK2MKNK1ABL1SRC | |
| Ast-487 SCHEMBL29391947 | 1.00 | HCK (1.00) | HCKMKNK2MKNK1ABL1SRC | |
| SCHEMBL4792487 | 0.93 | SRC (0.88) | HCKMKNK2MKNK1ABL1SRC | |
| SCHEMBL22528856 | 0.93 | HCK (0.86) | HCKMKNK2MKNK1ABL1SRC | |
| SCHEMBL4763945 | 0.93 | KDR (0.86) | HCKMKNK2MKNK1ABL1SRC | |
| SCHEMBL13991166 | 0.92 | HCK (0.85) | HCKMKNK2MKNK1ABL1SRC | |
| SCHEMBL13991080 | 0.91 | MAPK14 (0.84) | HCKMKNK2MKNK1ABL1SRC | |
| SCHEMBL4946054 | 0.91 | KDR (0.84) | HCKMKNK2MKNK1ABL1SRC | |
| SCHEMBL3183607 | 0.90 | SRC (0.82) | HCKMKNK2MKNK1ABL1SRC | |
| SCHEMBL22528877 | 0.90 | HCK (0.81) | HCKMKNK2MKNK1ABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020242910-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OFCALIFORNIA (US) | 2020-12-03 | — | — | WO | claimed |
| US-20190077856-A1 | METHOD OF TREATING DISEASES USING KINASE MODULATORS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-03-14 | — | — | US | claimed |
| WO-2017160717-A2 | METHOD OF TREATING DISEASES USING KINASE MODULATORS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2017-09-21 | — | — | WO | claimed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1511730-B1 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-12-10 | — | — | EP | claimed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | claimed |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4574214-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4308573-B1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHROEDINGER INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240368084-A1 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2024-11-07 | — | — | US | disclosed |
| US-12102621-B2 | Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-118319866-A | Formulations comprising RET kinase inhibitors | 罗索肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| WO-2011050319-A2 | INHIBITING THE DELETERIOUS EFFECT OF ANTHRACYCLINES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | RET 4/4885FLT3 16/4885HCK 371/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | RET 568/4885FLT3 923/4885HCK 377/4885 |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 | RET 3856/4885FLT3 1853/4885HCK 497/4885 |
| US-20240368084-A1 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | STING1, IRF3, CGAS | RET 2865/4885FLT3 252/4885HCK 1557/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | RET 5/4885FLT3 19/4885HCK 358/4885 |
| US-12102621-B2 | Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | RET 1/4885FLT3 196/4885HCK 68/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | RET 38/4885FLT3 89/4885HCK 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.